Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross IA Casgevy Policy Update | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IowaPolicy 05.05.34

    Casgevy (exagamglogene autotemcel) Coverage Criteria

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.05.34 alerts

    Get alerted when Policy 05.05.34 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for Casgevy in members with sickle cell disease or transfusion-dependent beta-thalassemia. Coverage requires indication-specific clinical, laboratory, treatment-history, specialist-prescriber, and safety criteria.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyCasgevy (exagamglogene autotemcel) Coverage Criteria
    Policy CodePolicy 05.05.34
    Change TypeNo material change
    Effective DateOct 3, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with the required clinical, genetic, and treatment-history information to initiate review.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2 yearsMinimum member age
    12 kgMinimum body weight
    3 monthsAuthorization duration
    1 per lifetimeTreatment limit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2
    Minimum severe VOEs per year
    100 mL/kg or 10 unitsMinimum pRBC transfusions per year

    Coverage Criteria

    Initial therapy — transfusion-dependent beta-thalassemia

    Covered for transfusion-dependent beta-thalassemia when ALL of the following are met:

    Transfusion-dependent beta-thalassemia initial approval

    • Member is 2 years of age or older.
    • Member weighs at least 12 kg.
    • Qualifying genotype

      • Molecular or genetic testing confirms a non-β0/β0 genotype.
      • Molecular or genetic testing confirms a β0/β0 genotype.
    • Member has received at least 100 mL/kg or 10 units of packed red blood cells per year during the previous 2 years.
    • No disqualifying condition

      • Member does not have associated alpha-thalassemia with greater than 1 alpha deletion or alpha multiplications.
      • Member does not have a sickle cell beta-thalassemia variant.
      • Member does not have a T2*-weighted MRI myocardial iron measurement below 10 msec or other evidence of severe iron overload in the opinion of the treating physician.
      • Member does not have a known 10/10 HLA-matched related donor willing to participate in an allogeneic HSCT.
      • Member does not have advanced liver disease, including persistent AST or ALT greater than 3 times the upper limit of normal, direct bilirubin greater than 2.5 times the upper limit of normal, baseline prothrombin time greater than 1.5 times the upper limit of normal, clear evidence of cirrhosis on liver MRI, or liver-biopsy evidence of cirrhosis, bridging fibrosis, or active hepatitis.
    • Member has a negative serologic test for HIV infection.
    • Member has not received a prior hematopoietic stem cell transplant (HSCT).
    • Member has not previously received Casgevy or any other gene therapy.

    Continuation and repeat therapy

    Repeat treatment is not covered.

    Lifetime treatment limitation

    • Repeat treatment of Casgevy for any indication is considered investigational and not medically necessary because safety and efficacy beyond one dose have not been studied.
    • Approval is limited to one treatment course per lifetime.One treatment course per lifetime

    Coverage requires that the member does not have a known 10/10 HLA-matched related donor willing to participate in allogeneic hematopoietic stem cell transplantation (HSCT).

    Coverage requires no advanced liver disease, defined by any of the following: persistent AST or ALT greater than 3 times the upper limit of normal; direct bilirubin greater than 2.5 times the upper limit of normal; baseline prothrombin time greater than 1.5 times the upper limit of normal; liver MRI showing clear cirrhosis; or liver biopsy showing cirrhosis, bridging fibrosis, or active hepatitis.

    Coverage requires no prior or current malignancy, except basal or squamous cell carcinoma of the skin, and no significant immunodeficiency disorder.

    Coverage requires no active bacterial, fungal, parasitic, or viral infection, including active or uncontrolled hepatitis B or hepatitis C infection.

    Coverage requires no contraindication or hypersensitivity to plerixafor, busulfan, G-CSF where applicable, or other medicinal products required during myeloablative conditioning, including hypersensitivity to active substances or excipients.

    Coverage requires a white blood cell count of at least 3 × 10^9/L and a platelet count of at least 50 × 10^9/L, unless the low counts are related to hypersplenism.

    For transfusion-dependent beta-thalassemia, coverage requires no associated alpha-thalassemia with greater than 1 alpha deletion or alpha multiplications.

    For transfusion-dependent beta-thalassemia, coverage requires no sickle cell beta-thalassemia variant.

    For transfusion-dependent beta-thalassemia, coverage requires no severe myocardial iron overload, defined as a T2*-weighted MRI myocardial iron measurement below 10 msec or other evidence of severe iron overload in the treating physician’s opinion.

    Repeat treatment of Casgevy for any indication is considered investigational and not medically necessary because safety and efficacy beyond one dose have not been studied. Approval is limited to one treatment course per lifetime.

    Casgevy is not medically necessary when the member does not meet the stated approval criteria.

    Coding and Clinical Thresholds

    Billing codesHCPCS
    J3392Injection, exagamglogene autotemcel, per treatment
    J3490Unclassified drugs (when specified as [Casgevy] (exagamglogene autotemcel))
    J3590Unclassified biologics (when specified as [Casgevy] (exagamglogene autotemcel))
    C9399Unclassified drugs or biologics (when specified as [Casgevy] (exagamglogene autotemcel))
    Liver transaminases
    ThresholdPersistent AST or ALT greater than 3 times the upper limit of normal
    Applies toAdvanced liver disease assessment
    Policy implicationA qualifying abnormality is an exclusion criterion for Casgevy approval
    Direct bilirubin
    ThresholdDirect bilirubin greater than 2.5 times the upper limit of normal
    Applies toAdvanced liver disease assessment
    Policy implication

    Provider Requirements and Action Items

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required before Casgevy treatment. Submit the clinical, genetic, and treatment-history information needed to confirm the applicable indication and approval criteria.

    • Clinical documentation supporting the diagnosis and disease severity
    • Molecular or genetic testing results confirming the applicable genotype
    • Treatment history, including vaso-occlusive episodes, hydroxyurea use, or transfusion dependence, as applicable
    Billing Rule

    Initial Authorization: 3 Months for One Dose

    When all applicable criteria are met, initial authorization is limited to 3 months for a single dose of Casgevy.

    Clinical Background

    Casgevy (exagamglogene autotemcel) is a gene therapy indicated for patients at least 2 years of age with sickle cell disease and recurrent vaso-occlusive crises, or with transfusion-dependent beta-thalassemia. The policy limits treatment to a single dose and requires evaluation of genotype, disease burden, transplant alternatives, organ function, infection status, blood counts, and the ability to receive required mobilization and myeloablative-conditioning medicines.

    Definitions and Examples

    Severe vaso-occlusive event
    EventAcute pain event
    Required settingRequires a visit to a medical facility
    Qualifying treatmentAdministration of opioids, intravenous non-steroidal anti-inflammatory drugs, or red blood cell transfusion
    Other examples of severe vaso-occlusive events
    Acute chest syndromeListed as a severe vaso-occlusive event
    PriapismLasting more than 2 hours and requiring a visit to a medical facility
    Splenic sequestration

    Initial Therapy Criteria

    Sickle cell disease — initial treatment

    Initial treatment for sickle cell disease requires ALL listed criteria.

    Sickle cell disease

    • Member is at least 2 years old.
    • Member weighs at least 12 kg.
    • Qualifying genotype

      • Molecular or genetic testing confirms βs/βs genotype.
      • Molecular or genetic testing confirms βs/β0 genotype.

    Continuation and Repeat Therapy

    One treatment course per lifetime

    Continuation or repeat therapy is not covered.

    • Repeat treatment of Casgevy for any indication is considered investigational and not medically necessary because safety and efficacy beyond one dose have not been studied.
    • Approval is limited to one treatment course per lifetime.One treatment course per lifetime

    Step Therapy Requirement

    StepPrior therapyCoverage requirement
    1HydroxyureaFor sickle cell disease, the member must have experienced hydroxyurea failure or have intolerance or inability to tolerate hydroxyurea.

    Quantity Limits

    Casgevy quantity limit
    Quantity limitOne treatment per lifetime
    Applies toCasgevy approvals
    Repeat treatmentRepeat treatment for any indication is investigational and not medically necessary
    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyCasgevy (exagamglogene autotemcel) Coverage Criteria
    Policy CodePolicy 05.05.34
    Change TypeNo material change
    Effective DateOct 3, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with the required clinical, genetic, and treatment-history information to initiate review.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsProvider Requirements and Action ItemsClinical BackgroundDefinitions and ExamplesInitial Therapy CriteriaContinuation and Repeat TherapyStep Therapy RequirementQuantity Limits
    Member does not have prior or current malignancy, except basal or squamous cell carcinoma of the skin, or a significant immunodeficiency disorder.
  1. Member does not have an active bacterial, fungal, parasitic, or viral infection, including active or uncontrolled HBV or HCV infection.
  2. Member does not have a contraindication or hypersensitivity to G-CSF, plerixafor, busulfan, or any other medicinal product required during myeloablative conditioning.
  3. Member does not have a white blood cell count below 3 × 10^9/L and/or platelet count below 50 × 10^9/L when not related to hypersplenism.
  4. A qualifying abnormality is an exclusion criterion for Casgevy approval
    Baseline prothrombin time
    ThresholdBaseline prothrombin time greater than 1.5 times the upper limit of normal
    Applies toAdvanced liver disease assessment
    Policy implicationA qualifying abnormality is an exclusion criterion for Casgevy approval
    Blood counts
    White blood cell countLess than 3 × 10^9/L
    Platelet countLess than 50 × 10^9/L
    QualificationCounts must not be related to hypersplenism; either or both thresholds apply
    Myocardial iron
    MRI thresholdT2*-weighted myocardial iron measurement less than 10 msec
    Alternative evidenceOther evidence of severe iron overload in the opinion of the treating physician
    Policy implicationEither finding is an exclusion criterion for transfusion-dependent beta-thalassemia approval
    Sickle cell vaso-occlusive events
    Minimum historyAt least 2 severe vaso-occlusive events per year
    Lookback periodDuring the previous 2 years
    DocumentationA documented history of severe vaso-occlusive events is required
    Packed red blood cell transfusions
    Minimum volumeAt least 100 mL/kg of packed red blood cells per year
    Alternative minimumAt least 10 units of packed red blood cells per year
    Lookback periodDuring the previous 2 years
    • Applies to both sickle cell disease and transfusion-dependent β-thalassemia
    • Authorization is for one single-dose treatment course
    Step Therapy

    Hydroxyurea Failure or Intolerance Required

    For sickle cell disease, document that the member has experienced hydroxyurea failure or has intolerance or inability to tolerate hydroxyurea.

    • Hydroxyurea failure, intolerance, or inability to tolerate hydroxyurea is required

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Denial Risk

    Sickle Cell Disease Exclusion Criteria

    For sickle cell disease, do not request approval when any listed exclusion applies. The member must also have a negative HIV serology and no prior HSCT, Casgevy treatment, or other gene therapy.

    • No known 10/10 HLA-matched related donor willing to participate in allogeneic HSCT
    • No advanced liver disease, including qualifying abnormal liver tests, cirrhosis, bridging fibrosis, or active hepatitis
    • No prior or current malignancy other than basal or squamous cell carcinoma of the skin, and no significant immunodeficiency disorder
    • No active bacterial, fungal, parasitic, or viral infection, including active or uncontrolled HBV or HCV infection
    • No contraindication to plerixafor, busulfan, or other required myeloablative-conditioning medications
    • White blood cell count is not less than 3 × 10^9/L and platelet count is not less than 50 × 10^9/L, unless related to hypersplenism
    • Negative serologic test for HIV; no prior HSCT, Casgevy, or other gene therapy
    Denial Risk

    Beta-Thalassemia Exclusion Criteria

    For transfusion-dependent β-thalassemia, do not request approval when any listed exclusion applies. The member must also have a negative HIV serology and no prior HSCT, Casgevy treatment, or other gene therapy.

    • No associated α-thalassemia with greater than one alpha deletion or alpha multiplications
    • No sickle cell beta-thalassemia variant
    • No severe myocardial or other iron overload, including T2*-weighted myocardial MRI measurement less than 10 msec or other severe iron overload determined by the treating physician
    • No known 10/10 HLA-matched related donor willing to participate in allogeneic HSCT
    • No advanced liver disease, including qualifying abnormal liver tests, cirrhosis, bridging fibrosis, or active hepatitis
    • No prior or current malignancy other than basal or squamous cell carcinoma of the skin, and no significant immunodeficiency disorder
    • No active bacterial, fungal, parasitic, or viral infection, including active or uncontrolled HBV or HCV infection
    • No contraindication to G-CSF, plerixafor, busulfan, or other required myeloablative-conditioning medications
    • White blood cell count is not less than 3 × 10^9/L and platelet count is not less than 50 × 10^9/L, unless related to hypersplenism
    • Negative serologic test for HIV; no prior HSCT, Casgevy, or other gene therapy
    Denial Risk

    Repeat Treatment Denied; One Course per Lifetime

    Repeat treatment of Casgevy for any indication is considered investigational because safety and efficacy beyond one dose have not been established. Approval is limited to one treatment course per lifetime.

    • Do not approve repeat treatment
    • Lifetime limit: one Casgevy treatment course
    Note

    Indication and Benefit Requirements

    Casgevy is covered only for an FDA-approved or otherwise covered indication when all applicable approval criteria are met and no exclusion applies.

    • Sickle cell disease in patients age 2 years or older with recurrent vaso-occlusive crises
    • Transfusion-dependent β-thalassemia in patients age 2 years or older
    • Coverage remains subject to the applicable clinical criteria and benefit exclusions
    Listed as a severe vaso-occlusive event
    Hepatic sequestrationListed as a severe vaso-occlusive event
    Severe vaso-occlusive events
    Acute pain eventRequires a medical-facility visit and administration of opioids, intravenous NSAIDs, or red blood cell transfusion
    Acute chest syndromeQualifies as a severe vaso-occlusive event
    PriapismMust last more than 2 hours and require a medical-facility visit
    Splenic sequestrationQualifies as a severe vaso-occlusive event
    Hepatic sequestrationQualifies as a severe vaso-occlusive event
    Nonβ0/β0 or β0/β0 genotypes
    Genotype 1β0/β0
    Genotype 2β0/β+
    Genotype 3βE/β0
    Genotype 4β0/IVS-I-110
    Genotype 5IVS-I-110/IVS-1-110
    Molecular or genetic testing confirms βs/β+ genotype.
  5. Member has at least 2 severe vaso-occlusive episodes per year during the previous 2 years.
  6. Member has experienced hydroxyurea failure or has intolerance or inability to tolerate hydroxyurea.
  7. No disqualifying condition

    • Member does not have a known 10/10 HLA-matched related donor willing to participate in an allogeneic HSCT.
    • Member does not have advanced liver disease.
    • Member does not have prior or current malignancy, except basal or squamous cell carcinoma of the skin, or a significant immunodeficiency disorder.
    • Member does not have an active bacterial, fungal, parasitic, or viral infection, including active or uncontrolled HBV or HCV infection.
    • Member does not have a contraindication or hypersensitivity to plerixafor, busulfan, or any other medicinal product required during myeloablative conditioning.
    • Member does not have a white blood cell count below 3 × 10^9/L and/or platelet count below 50 × 10^9/L when not related to hypersplenism.
  8. Member has a negative HIV serologic test.
  9. Member has no prior HSCT.
  10. Member has not previously received Casgevy or any other gene therapy.
  11. Transfusion-dependent beta-thalassemia — initial treatment

    Initial treatment for transfusion-dependent beta-thalassemia requires ALL listed criteria.

    Transfusion-dependent beta-thalassemia

    • Member is at least 2 years old.
    • Member weighs at least 12 kg.
    • Qualifying genotype

      • Molecular or genetic testing confirms a non-β0/β0 genotype.
      • Molecular or genetic testing confirms a β0/β0 genotype.
    • Member has received at least 100 mL/kg or 10 units of packed red blood cells per year during the previous 2 years.
    • No disqualifying condition

      • Member does not have associated alpha-thalassemia with greater than 1 alpha deletion or alpha multiplications.
      • Member does not have a sickle cell beta-thalassemia variant.
      • Member does not have a T2*-weighted MRI myocardial iron measurement below 10 msec or other evidence of severe iron overload in the opinion of the treating physician.
      • Member does not have a known 10/10 HLA-matched related donor willing to participate in an allogeneic HSCT.
      • Member does not have advanced liver disease.
      • Member does not have prior or current malignancy, except basal or squamous cell carcinoma of the skin, or a significant immunodeficiency disorder.
    • Member has a negative HIV serologic test.
    • Member has no prior HSCT.
    • Member has not previously received Casgevy or any other gene therapy.
    Member does not have an active bacterial, fungal, parasitic, or viral infection, including active or uncontrolled HBV or HCV infection.
  12. Member does not have a contraindication or hypersensitivity to G-CSF, plerixafor, busulfan, or any other medicinal product required during myeloablative conditioning.
  13. Member does not have a white blood cell count below 3 × 10^9/L and/or platelet count below 50 × 10^9/L when not related to hypersplenism.